Brimonidine Tartrate NDC 62332-749

NDC codes

FDA NDC Directory

Product NDC (as listed)62332-749Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62332-0749Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
62332-749-05	62332074905	1 BOTTLE in 1 CARTON (62332-749-05) / 5 mL in 1 BOTTLEMarketed from Aug 1, 2023
62332-749-10	62332074910	1 BOTTLE in 1 CARTON (62332-749-10) / 10 mL in 1 BOTTLEMarketed from Aug 1, 2023
62332-749-15	62332074915	1 BOTTLE in 1 CARTON (62332-749-15) / 15 mL in 1 BOTTLEMarketed from Aug 1, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Brimonidine Tartrate
Generic name (nonproprietary): brimonidine tartrate
Active ingredients: Brimonidine tartrate — 1 mg/mL
Dosage form: Solution/ drops
Route: Ophthalmic
Labeler: Alembic Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 216909
Marketing start: Aug 1, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Adrenergic alpha-Agonists (Mechanism)
Identifiers: Product ID 62332-749_31b081e9-14ff-4b24-a21f-14ab41d8c0f8SPL ID 31b081e9-14ff-4b24-a21f-14ab41d8c0f8SPL set ID 9da815fb-6454-4925-9150-bec40eff9c2dRxCUI 861204UNII 4S9CL2DY2H
Pharmacologic class: alpha-Adrenergic Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Ophthalmic products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462332074905 followed by a unit qualifier and the quantity

Package 62332-0749-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 11, 2023.

Indications (excerpt from the label)

Brimonidine tartrate ophthalmic solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension Brimonidine Tartrate Ophthalmic Solution is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)